<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20713" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Drug and Alcohol Use (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Alozai</surname>
            <given-names>Ubaid ullah</given-names>
          </name>
          <aff>Allama Iqbal Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Mery Fitzgerald Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ubaid ullah Alozai declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20713.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Drug and alcohol abuse is a common societal problem worldwide.</p>
        <p>
<bold>Drug/Substance</bold>
<bold> Abuse</bold>
</p>
        <p>Drug abuse refers to the excessive use of drugs that tends to activate the brain reward system that reinforces behaviors and the production of memories. Substance abuse has been adopted by the <italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)</italic> to include 10 separate classes of drugs, including alcohol, caffeine, cannabis, hallucinogens, inhalants, opioids, sedatives, hypnotics and anxiolytics, stimulants, tobacco, and other substances.&#x000a0;These drugs produce such an intense activation of the reward system that normal activities may be neglected. Instead of achieving reward through adaptive behaviors, drugs of abuse directly activate the reward pathways. Each class of drugs produces different pharmacological mechanisms, but the drugs typically activate the system and produce a feeling of pleasure, often referred to as a high.</p>
        <p>Substance-induced disorders include intoxication, withdrawal, and substance-induced mental disorders such as psychotic disorders, bipolar disorder, depressive disorder, anxiety disorder, obsessive-compulsive disorder, sleep disorders, sexual dysfunction, delirium, and neurocognitive disorders.</p>
        <p>
<bold>Alcohol Abuse</bold>
</p>
        <p>Alcohol abuse refers to drinking too much alcohol on occasion, as well as habits of drinking alcohol that result in harm to health, ability to work behavior, and judgment. Alcohol abusers generally are not dependent on alcohol. On the other hand, alcohol dependence means a person needs alcohol to get through their day. Alcohol abuse and alcohol dependency were previous terms used in DSM-IV. DSM-5 has combined alcohol abuse and alcohol dependence to create a unified disorder, alcohol use disorder (AUD).<xref ref-type="bibr" rid="article-20713.r1">[1]</xref><xref ref-type="bibr" rid="article-20713.r2">[2]</xref><xref ref-type="bibr" rid="article-20713.r3">[3]</xref></p>
      </sec>
      <sec id="article-20713.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>
<bold>Drug/Substance</bold>
<bold>&#x000a0;Abuse</bold>
</p>
        <p>
<bold>Family Risk Factors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Parental drug/alcohol use</p>
          </list-item>
          <list-item>
            <p>Intrauterine exposure to drugs</p>
          </list-item>
          <list-item>
            <p>Marital conflict</p>
          </list-item>
          <list-item>
            <p>family dysfunction</p>
          </list-item>
          <list-item>
            <p>Use among siblings</p>
          </list-item>
          <list-item>
            <p>Recent trauma</p>
          </list-item>
          <list-item>
            <p>Parent-child conflict, child abuse</p>
          </list-item>
        </list>
        <p>
<bold>Individual Risk Factors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Difficult temperament/inflexibility, low positive mood, withdrawal&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Irritability&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Motor, language, and cognitive impairments&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Early aggressive behavior&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Poor social skills: impulsive, aggressive, passive, and withdrawn&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Poor social problem-solving skills&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Sensation-seeking&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lack of behavioral self-control&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Early persistent behavior problems/antisocial behavior&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Attention-deficit/hyperactivity disorder&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Poor impulse control/impulsivity, poor concentration&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Low self-esteem, perceived incompetence, negative explanatory and inferential style&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Poor grades/achievements/school failure, low commitment to school&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Peer Risk Factors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Substance-using peers</p>
          </list-item>
          <list-item>
            <p>Attending college</p>
          </list-item>
          <list-item>
            <p>Deviant peer group</p>
          </list-item>
        </list>
        <p>
<bold>Community Risk Factors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Law and norms about alcohol and drug use</p>
          </list-item>
          <list-item>
            <p>Availability of the drug</p>
          </list-item>
        </list>
        <p>
<bold>Co-occurring Disorders</bold>
</p>
        <p>There is a high rate of co-occurring mental disorders among adolescent youth (12 to 18 years) who use substances or have a substance use disorder, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Conduct disorder</p>
          </list-item>
          <list-item>
            <p>Attention deficit hyperactivity disorder</p>
          </list-item>
          <list-item>
            <p>Major depressive disorder</p>
          </list-item>
          <list-item>
            <p>Bipolar disorder</p>
          </list-item>
          <list-item>
            <p>Anxiety disorder</p>
          </list-item>
          <list-item>
            <p>Schizophrenia</p>
          </list-item>
          <list-item>
            <p>Post-traumatic stress disorder (PTSD)</p>
          </list-item>
        </list>
        <p>In studies of children 13 to 18 years of age with a mental disorder, rates of a co-occurring substance use disorder (SUD) have ranged from 61% to 88%.</p>
        <p>
<bold>Alcohol Abuse</bold>
</p>
        <p>Alcoholism is etiologically complex, with a variety of other vulnerability factors.</p>
        <p>
<bold>Environmental Factors</bold>
</p>
        <p>It has been estimated that there is a 7-fold risk of alcoholism in first-degree relatives of alcohol-dependent individuals, with male relatives of male alcohol-dependent individuals having the greatest risk for the disorder.</p>
        <p>
<bold>Genetic Factors</bold>
</p>
        <p>Among type 1 and type 2 alcoholics (typologies developed by Cloninger), type 1 alcoholics are characterized by the late onset of problem drinking, the rapid development of behavioral tolerance to alcohol, prominent guilt and anxiety related to drinking, and infrequent fighting and arrests when drinking. Cloninger also termed this subtype &#x0201c;milieu-limited,&#x0201d; which emphasizes the etiologic role of environmental factors. In contrast, type 2 alcoholics are characterized by early onset of an inability to abstain from alcohol, frequent fighting and arrests when drinking, and the absence of guilt and fear concerning drinking. Cloninger postulated that transmission of alcoholism in type 2 alcoholics was from fathers to sons, hence term the male-limited alcoholism. Type 1 alcoholics are characterized by high-reward dependence, high-harm avoidance, and low-novelty seeking. In contrast, type 2 alcoholics are characterized by high-novelty seeking, low-harm avoidance,&#x000a0;and low-reward dependence. Cloninger also hypothesized that specific neurotransmitter systems underlie personality structure. Specifically, dopamine is hypothesized to modulate novelty seeking, characterized by frequent exploratory behavior and intensely pleasurable responses to novel stimuli. Serotonin is hypothesized to modulate harm avoidance, which is a tendency to respond intensely to aversive stimuli and their conditioned signals. Finally, norepinephrine is hypothesized to modulate reward dependence or the resistance to extinction of previously rewarded behavior.</p>
        <p>
<bold>Pharmacological Vulnerability</bold>
</p>
        <p>Some studies show a decreased sensitivity to the effects of alcohol in adult children of alcoholics. Other data indicate the effects of the alcohol metabolizing enzymes aldehyde dehydrogenase and alcohol dehydrogenase polymorphisms in individuals of Asian ancestry, in which adverse reactions to the effects of alcohol are associated with reduced risk of alcohol dependence. Flushing reaction happens to individuals homozygous for the gene that codes the enzyme, aldehyde dehydrogenase (ALDH2). This enzyme breaks down acetaldehyde, one of the byproducts of alcohol metabolism includes the GABRG1 and GABRA2 genes that encode the gamma-1 and alpha-2 subunits of the GABA-A receptor, COMT Val158Met, and DRD2 Taq1A, which may affect dopamine receptor sensitivity, and KIAA0040. Genes may influence which individuals are more susceptible to alcohol-related comorbidities like alcoholic liver disease.</p>
        <p>
<bold>Affective Deregulation</bold>
</p>
        <p>It is proposed that alcoholism is caused by repeated alcohol use to &#x0201c;self-medicate&#x0201d; negative affective states such as anxiety and depression.</p>
        <p>
<bold>Personality Disorders</bold>
</p>
        <p>These include hyperactivity, distractibility, sensation seeking, impulsivity, difficult temperament, and conduct disorder.<xref ref-type="bibr" rid="article-20713.r1">[1]</xref><xref ref-type="bibr" rid="article-20713.r4">[4]</xref><xref ref-type="bibr" rid="article-20713.r5">[5]</xref></p>
      </sec>
      <sec id="article-20713.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>
<bold>Drug/Substance</bold>
<bold>&#x000a0;Abuse</bold>
</p>
        <p>Substantial proportions of youth surveyed had tried illicit drugs at least once in the countries that follow.</p>
        <list list-type="bullet">
          <list-item>
            <p>Australia (greater than 40%),&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Canada (greater than35%),&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Europe (greater than&#x000a0;23% boys, 17% girls),&#x000a0;</p>
          </list-item>
          <list-item>
            <p>United States (greater than 40%, more than 25% of 8th graders,&#x000a0;</p>
          </list-item>
        </list>
        <p>Nearly half of 12th graders in the United States reported smoking marijuana daily, and 1 in 7 reported having been a daily marijuana smoker at some time for at least a month.</p>
        <p>The rate of current illicit drug use among European youth ages 12 to 17 was 9.5% in 2012, with the&#x000a0;percentage of users as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>7.2% Marijuana</p>
          </list-item>
          <list-item>
            <p>2.8% Nonmedical use of the prescription drug (1.8 percent pain reliever)</p>
          </list-item>
          <list-item>
            <p>0.8% Inhalants</p>
          </list-item>
          <list-item>
            <p>0.6% Hallucinogens</p>
          </list-item>
          <list-item>
            <p>0.5% Heroin</p>
          </list-item>
          <list-item>
            <p>0.1% Cocaine</p>
          </list-item>
        </list>
        <p>
<bold>Alcohol Abuse</bold>
</p>
        <p>Alcohol use disorder is a common disorder in the United States. The 12-month prevalence of alcohol use disorder is estimated to be 4.6% among 12 to 17-year-olds and 8.5% among adults aged 18 years and older in the United States. Rates of the disorder are greater among adult men (12.4%) than among adult women (4.9%). Twelve-month prevalence of alcohol use disorder among adults decreases in middle age, being greatest among 18 to 29-years-olds (16.2%) and lowest among individuals age 65 years and older (1.5%). The twelve-month prevalence varies markedly across race/ethnic subgroups of the US population. For 12 to 17-year-olds, rates are greatest among Hispanics (6.0%) and Native Americans and Alaska Natives (5.7%) relative to whites (5.0%), African Americans (1.8%), and Asian Americans and Pacific Islanders (1.6%). In contrast, among adults, the 12-month prevalence of alcohol use disorder is clearly greater among Native Americans and Alaska Natives (12.1%) than among whites (8.9%), Hispanics (7.9%), African Americans (6.9%), and Asian Americans and Pacific Islanders (4.5%).</p>
        <p>The 2011 US National Survey on Drug Use and Health estimated that of Americans over the age of 12 in the past 30 days:</p>
        <list list-type="bullet">
          <list-item>
            <p>52.7% used alcohol at least once&#x000a0;</p>
          </list-item>
          <list-item>
            <p>23% reported binge drinking (defined by the survey as 5 or more drinks on one occasion</p>
          </list-item>
          <list-item>
            <p>6.2% reported heavy drinking (defined as 5 or more drinks on each of 5 or more days)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20713.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Drug/Substance</bold>
<bold>&#x000a0;Abuse</bold>
</p>
        <p>As with most behavioral and psychiatric disorders, the interplay between genetic risk, temperamental traits, and the environment may predispose to early use of substances of abuse. Once exposed to substances, brain reward systems reinforce substance use, resulting in repeated use and lower ability to control substance use.</p>
        <p>
<bold>Alcohol Abuse</bold>
</p>
        <p>The pathophysiology of alcohol use disorder is not known, but its development may result from a complex interplay of genetics, environmental factors, personality traits, and cognitive functioning.</p>
      </sec>
      <sec id="article-20713.s5" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>
<bold>Drug/Substance</bold>
<bold>&#x000a0;Abuse</bold>
</p>
        <p>Substance use and/or substance use disorders (SUDs) are associated with many negative consequences among youth, including accidents, death, health effects, crime, unplanned pregnancy, and lower achievement. Substance use contributes to accidents, death, and a variety of hazardous behaviors. Sexual behaviors are increased during adolescent substance use. Toxic effects of different drugs of abuse include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Opioids: Respiratory and central nervous system (CNS) depression, increased risk of aspiration due to a diminished gag reflex, pupillary constriction, seizures, and euphoria</p>
          </list-item>
          <list-item>
            <p>Barbiturates: Results in marked respiratory depression</p>
          </list-item>
          <list-item>
            <p>Benzodiazepines: Results in minor respiratory depression</p>
          </list-item>
          <list-item>
            <p>Amphetamine:&#x000a0;Results in euphoria, grandiosity, pupillary dilation, prolonged wakefulness and attention, hypertension, tachycardia, anorexia, fever, and paranoia. Severe intoxication can cause cardiac arrest and seizures.</p>
          </list-item>
          <list-item>
            <p>Cocaine:&#x000a0;Impaired judgment, pupillary dilation, hallucinations, paranoid ideation, angina, and sudden cardiac death</p>
          </list-item>
          <list-item>
            <p>Caffeine:&#x000a0;In restlessness and muscle twitching</p>
          </list-item>
          <list-item>
            <p>Nicotine: restlessness</p>
          </list-item>
          <list-item>
            <p>Phencyclidine:&#x000a0;Violence, impulsivity, psychomotor agitation, nystagmus, tachycardia, hypertension, analgesia, psychosis, delirium, and seizures</p>
          </list-item>
          <list-item>
            <p>LSD:&#x000a0;Visual and auditory hallucinations, depersonalization, anxiety, paranoia, psychosis, and flashbacks</p>
          </list-item>
          <list-item>
            <p>Marijuana: Euphoria, anxiety, paranoid delusions, the perception of slowed time, impaired judgment, amotivational syndrome, dry mouth, increased appetite, conjunctival injection, and hallucinations</p>
          </list-item>
          <list-item>
            <p>MDMA:&#x000a0;Euphoria, disinhibition, hyperactivity, life-threatening hypertension, tachycardia, hyperthermia, hypernatremia, and serotonin syndrome</p>
          </list-item>
        </list>
        <p>
<bold>Alcohol Abuse</bold>
</p>
        <p>Excessive alcohol consumption is the third leading preventable cause of death in the United States. More than 85,000 deaths a year in the United States&#x000a0;are directly attributed to alcohol use.</p>
        <list list-type="bullet">
          <list-item>
            <p>Toxicity: Emotional lability, slurred speech, ataxia, blackouts<xref ref-type="bibr" rid="article-20713.r6">[6]</xref><xref ref-type="bibr" rid="article-20713.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20713.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Drug/Substance</bold>
<bold>&#x000a0;Abuse</bold>
</p>
        <p>
<bold>History</bold>
</p>
        <p>A detailed history&#x000a0;is necessary to establish the diagnosis of drug abuse.&#x000a0;A patient&#x02019;s social history can provide information about risk factors for unhealthy substance use and the impact of substance use on the patient&#x02019;s role functioning. Look for a partner with a substance use disorder, poor socio-economic&#x000a0;society, violence, high school alcohol, and other drug availability. A&#x000a0;family history of substance use disorder (SUD) has been shown to be a risk factor for developing a substance abuse disorder. Heritability estimates range from:</p>
        <list list-type="bullet">
          <list-item>
            <p>50% to 70% for alcohol use disorder</p>
          </list-item>
          <list-item>
            <p>From 34% to 78% for cannabis use disorder</p>
          </list-item>
          <list-item>
            <p>42% to 79% percent for cocaine use disorder</p>
          </list-item>
          <list-item>
            <p>23% to 54% for opioid use disorder</p>
          </list-item>
        </list>
        <p>Dig&#x000a0;deep into a history of Disrupted familial and social relationships, failure to fulfill responsibilities at school or work (e.g., loss of job, poor grades in school. Ask questions about any past history of violent behavior, child abuse, financial problems, and sexual history (multiple partners, sex habits, etc.)</p>
        <p>
<bold>Physical Exam</bold>
</p>
        <p>During the physical examination, look for:</p>
        <list list-type="bullet">
          <list-item>
            <p>Poor personal hygiene</p>
          </list-item>
          <list-item>
            <p>Significant weight loss or weight gain&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Signs of injection drug use including scars at injection sites (so-called &#x0201c;track marks&#x0201d;) on the skin</p>
          </list-item>
          <list-item>
            <p>Signs of drug inhalation including atrophy of the nasal mucosa and perforation of the nasal septum</p>
          </list-item>
          <list-item>
            <p>Evidence of acute intoxication or withdrawal, such as slurred speech, unsteady gait, pinpoint pupils, bizarre or atypical behavior, changes in the level of arousal (agitation or sedation), tachycardia, euphoria, etc. conjunctival injection, sweating, watery eyes, runny nose.</p>
          </list-item>
        </list>
        <p>
<bold>Mental State Exam</bold>
</p>
        <p>This examination should be performed and look for the following symptoms and signs:</p>
        <list list-type="bullet">
          <list-item>
            <p>Behavior: Aroused, agitated, or sedated.</p>
          </list-item>
          <list-item>
            <p>Appearance: Personal hygiene, clothes,&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Speech and Voice: Slurred or pressured</p>
          </list-item>
          <list-item>
            <p>Mood: Euphoria, elated mood, depressed mood</p>
          </list-item>
          <list-item>
            <p>Perception: Hallucination</p>
          </list-item>
          <list-item>
            <p>Thoughts: Paranoia, delusions.</p>
          </list-item>
          <list-item>
            <p>Insight: Poor insight</p>
          </list-item>
          <list-item>
            <p>Cognition: Decreased concentration span, disorientation, amnesia</p>
          </list-item>
          <list-item>
            <p>Judgment: Altered</p>
          </list-item>
        </list>
        <p>
<bold>Alcohol Abuse</bold>
</p>
        <p>
<bold>History</bold>
</p>
        <p>Ask about current and past alcohol use and treatment,&#x000a0;family history of alcohol problems and treatment, and a detailed history regarding the quantity and frequency of alcohol use.</p>
        <p>
<bold>Physical</bold>
</p>
        <p>Physical features accompanying alcohol abuse range from a normal physical exam to features of alcohol withdrawal (tachycardia, tremor, agitation, clouding of the sensorium) to features of the advanced liver disease in case of chronic alcoholism (spider angiomata, palmar erythema, gynecomastia, testicular atrophy, hepatic or splenic enlargement).<xref ref-type="bibr" rid="article-20713.r1">[1]</xref></p>
      </sec>
      <sec id="article-20713.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>DSM-5 Diagnostic Criteria for Substance&#x000a0;Use Disorder</bold>
</p>
        <p>Two or more of the following in a 12-month period manifests a problematic pattern of use leading to clinically significant impairment or distress:</p>
        <list list-type="order">
          <list-item>
            <p>Often taken in larger amounts or over a longer period than was intended</p>
          </list-item>
          <list-item>
            <p>A persistent desire or unsuccessful efforts to cut down or control use</p>
          </list-item>
          <list-item>
            <p>A great deal of time is spent in activities necessary to obtain, use, or recover from the substance&#x02019;s effects</p>
          </list-item>
          <list-item>
            <p>Craving or a strong desire or urge to use the substance.</p>
          </list-item>
          <list-item>
            <p>Recurrent use resulting in a failure to fulfill major role obligations at work, school, or home</p>
          </list-item>
          <list-item>
            <p>Continued use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by its effects</p>
          </list-item>
          <list-item>
            <p>Important social, occupational, or recreational activities are given up or reduced because of use.</p>
          </list-item>
          <list-item>
            <p>Recurrent use in situations in which it is physically hazardous.</p>
          </list-item>
          <list-item>
            <p>Continued use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance</p>
          </list-item>
          <list-item>
            <p>Tolerance</p>
          </list-item>
          <list-item>
            <p>Withdrawal</p>
          </list-item>
        </list>
        <p><bold>Disorder Severity</bold>: DSM-5 specifies mild, moderate, and severe based on the number of diagnostic criteria met by the patient at the time of diagnosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild: Two to&#x000a0;3 criteria&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Moderate: Four4 to 5 criteria&#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Severe: Six or more criteria</p>
          </list-item>
        </list>
        <p>
<bold>DSM-5 Diagnostic Criteria for Alcohol Use Disorder</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Recurrent drinking resulting in failure to fulfill role obligations</p>
          </list-item>
          <list-item>
            <p>Recurrent drinking in hazardous situations&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Continued drinking despite alcohol-related social or interpersonal problems</p>
          </list-item>
          <list-item>
            <p>Evidence of tolerance</p>
          </list-item>
          <list-item>
            <p>Evidence of alcohol withdrawal or use of alcohol for relief or avoidance of withdrawal</p>
          </list-item>
          <list-item>
            <p>Drinking in larger amounts or over longer periods than intended</p>
          </list-item>
          <list-item>
            <p>Persistent desire or unsuccessful attempts to stop or reduce drinking</p>
          </list-item>
          <list-item>
            <p>A great deal of time spent obtaining, using, or recovering from alcohol</p>
          </list-item>
          <list-item>
            <p>Important activities are given up or reduced because of drinking</p>
          </list-item>
          <list-item>
            <p>Continued drinking despite knowledge of physical or psychological problems caused by alcohol</p>
          </list-item>
          <list-item>
            <p>Alcohol Craving</p>
          </list-item>
        </list>
        <p><bold>Disorder Severity</bold>: The severity of alcohol use disorder at the time of diagnosis can be specified as a subtype based on the number of symptoms present:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild: Two to&#x000a0;3 symptoms&#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Moderate: Four to&#x000a0;5 symptoms</p>
          </list-item>
          <list-item>
            <p>Severe: Six or more symptoms</p>
          </list-item>
        </list>
        <p>
<bold>Laboratory Tests</bold>
</p>
        <p>
<bold>Substance Abuse</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Drug of abuse screen</p>
          </list-item>
          <list-item>
            <p>Urine drug levels</p>
          </list-item>
          <list-item>
            <p>Blood drug levels</p>
          </list-item>
          <list-item>
            <p>Hair&#x000a0;drug levels</p>
          </list-item>
          <list-item>
            <p>Saliva drug levels</p>
          </list-item>
          <list-item>
            <p>Breath drug levels</p>
          </list-item>
        </list>
        <p>
<bold>Alcohol</bold>
</p>
        <p>Diagnosis of alcohol problem can be made in the outpatient department by using the CAGE questionnaire, which includes the questions: (need to) cut down, annoyance (on drinking), guilt (about drinking), an "eye-opener."</p>
        <p>Screening tools like the 10 question Alcohol Use Disorder Identification Test (AUDIT) and the abbreviated 3-question audit-consumption (Audit-C) are recommended for screening.</p>
        <p>Laboratory tests to confirm the diagnosis include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum alcohol concentration</p>
          </list-item>
          <list-item>
            <p>Direct alcohol biomarkers: Ethyl glucuronide.</p>
          </list-item>
          <list-item>
            <p>Liver enzymes: Aspartate aminotransferase (AST), alanine aminotransferase&#x000a0;(ALT), bilirubin, and albumin test for liver damage. An AST: ALT ratio of 2:1 is indicative of alcohol-induced liver disease</p>
          </list-item>
          <list-item>
            <p>Hemoglobin, complete blood count (CBC): To determine the presence and severity of anemia, pancytopenia, and macrocytosis. A mean corpuscular volume greater than 100 fL constitutes macrocytosis. Pancytopenia and macrocytosis usually require very heavy&#x000a0;and prolonged use and often liver disease.</p>
          </list-item>
          <list-item>
            <p>Gamma-glutamyltransferase (GGT): Is an indicator of excessive alcohol use when elevated (normal reference ranges: 8 to 40 units/L for females and 9 to 50 units/L for males).</p>
          </list-item>
          <list-item>
            <p>The patient's social network, especially family, should be involved in treatment to the extent possible (and agreed to by the patient, if a legally competent adult), to provide additional history and therapeutic support and help monitor the patient's progress and adherence to treatment.<xref ref-type="bibr" rid="article-20713.r1">[1]</xref><xref ref-type="bibr" rid="article-20713.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20713.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p><bold>Psychosocial Interventions</bold>&#x000a0; &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Enhance motivation to reduce or end cannabis use&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Improve social skills&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Improve social support and interpersonal functioning</p>
          </list-item>
          <list-item>
            <p>Manage painful feelings</p>
          </list-item>
          <list-item>
            <p>Education about consequences of drug use</p>
          </list-item>
        </list>
        <p>
<bold>Cognitive-Behavioral&#x000a0;Therapy</bold>
</p>
        <p>CBT is used to help patients learn how their thought processes play a role in developing their behavior. Cognitive awareness helps them develop new ways of behaving, thus leading to change in thinking patterns and emotions.</p>
        <p>
<bold>Mutual Help Groups</bold>
</p>
        <p>Alcoholics Anonymous (AA) is a voluntary program for people with alcoholism/AUD, based on belief in a spiritual basis for recovery. Members attend meetings, and experiences are shared, and "Twelve steps towards Recovery" are discussed. Avoiding alcohol and the benefits of avoiding alcohol are discussed. Abstinence is encouraged on a daily or weekly basis. Alcoholics Anonymous can be reached via their website www.aa.org.</p>
        <p>
<bold>Motivational Interviewing/Motivational Enhancement</bold>
</p>
        <p>
<bold>Drug or Addiction Counseling&#x000a0;</bold>
</p>
        <p>
<bold>Pharmacotherapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Alcohol:&#x000a0;As many as 70% of individuals relapse after psychosocial treatment alone</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>Naltrexone in toxicity and Supportive care.</p>
          </list-item>
          <list-item>
            <p>Naltrexone can be started while the patient is still drinking. Disulfiram should be used by abstinent patients to maintain abstinence, while acamprosate should be used once abstinence is achieved.</p>
          </list-item>
          <list-item>
            <p>Disulfiram should only be used in patients who are highly motivated to maintain abstinence.</p>
          </list-item>
          <list-item>
            <p>Treat Wernicke-Korsakoff with vitamin B-1 (thiamine) intravenously.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Opioids Intoxication: naloxone</p>
          </list-item>
          <list-item>
            <p>Opioids Withdrawal: methadone</p>
          </list-item>
          <list-item>
            <p>Barbiturate intoxication: Artificial ventilatory support.</p>
          </list-item>
          <list-item>
            <p>Benzodiazepines intoxication: Flumazenil</p>
          </list-item>
          <list-item>
            <p>Benzodiazepine withdrawal: Benzodiazepines&#x000a0;having a long half-life. Gradually cutting the dose down.</p>
          </list-item>
          <list-item>
            <p>Amphetamine intoxication: Benzodiazepines for agitation and seizures</p>
          </list-item>
          <list-item>
            <p>Cocaine intoxication: Alpha-blockers and benzodiazepines</p>
          </list-item>
          <list-item>
            <p>Caffeine intoxication: Symptomatic support</p>
          </list-item>
          <list-item>
            <p>Nicotine intoxication: Symptomatic support</p>
          </list-item>
          <list-item>
            <p>Nicotine withdrawal: Nicotine patch/gum, varenicline, bupropion</p>
          </list-item>
          <list-item>
            <p>Phencyclidine intoxication: Benzodiazepines and rapid-acting antipsychotics</p>
          </list-item>
          <list-item>
            <p>Marijuana: N-acetyl cysteine, gabapentin, and dronabinol<xref ref-type="bibr" rid="article-20713.r1">[1]</xref><xref ref-type="bibr" rid="article-20713.r9">[9]</xref><xref ref-type="bibr" rid="article-20713.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20713.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Psychosis</p>
          </list-item>
          <list-item>
            <p>Schizophrenia</p>
          </list-item>
          <list-item>
            <p>Mania</p>
          </list-item>
          <list-item>
            <p>Bipolar disorder</p>
          </list-item>
          <list-item>
            <p>Organic brain disorder</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20713.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis depends upon follow-up and motivational and cognitive behavior therapy. Support like Alcoholics-Anonymous groups plays an important role in prognosis.</p>
      </sec>
      <sec id="article-20713.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Substance use leads to a number of problems among youth, including accidents, death, health effects, crime, unplanned pregnancy, and lower achievement.</p>
      </sec>
      <sec id="article-20713.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Psychiatric consultation is necessary.</p>
      </sec>
      <sec id="article-20713.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Cognitive-behavioral therapy (CBT), motivational therapy, and psychotherapy are necessary to avoid remission.</p>
      </sec>
      <sec id="article-20713.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of alcohol and drug abuse requires an interprofessional team that includes a mental health nurse, psychiatrist, emergency department physician, internist, addiction counselor, pharmacist, and pain specialist. Clinicians need to be proactive and identify these patients; the earlier the treatment is undertaken, the better the outcomes. In addition, healthcare workers need to curtail the liberal prescription of analgesics, hypnotics, and sedatives and offer patients alternative means of managing their pain and insomnia. Pharmacists may be well-positioned to notice patterns of drug-seeking behavior and report this to the prescribing clinicians. Interprofessional team coordination and information sharing can bring about more positive outcomes for these patients. [Level 5]</p>
        <p>Unfortunately, the outcomes for patients addicted to alcohol and drugs are poor. Short-term recovery does occur, but relapses are common. Drug and alcohol addiction has repercussions beyond health; it can destroy the family, result in job loss and lead to financial loss.</p>
      </sec>
      <sec id="article-20713.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20713&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20713">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20713/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20713">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20713.s16">
        <title>References</title>
        <ref id="article-20713.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huckle</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Romeo</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Callinan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mackintosh</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Piazza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chaiyasong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cuong</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Casswell</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Socio-economic disadvantage is associated with heavier drinking in high but not middle-income countries participating in the International Alcohol Control Study.</article-title>
            <source>Drug Alcohol Rev</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>37 Suppl 2</volume>
            <issue>Suppl Suppl 2</issue>
            <fpage>S63</fpage>
            <page-range>S63-S71</page-range>
            <pub-id pub-id-type="pmid">29707842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20713.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prabhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McFall</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Srikrishnan</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shanmugam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Celentano</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Lucas</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Psychosocial Barriers to Viral Suppression in a Community-based Sample of Human Immunodeficiency Virus-infected Men Who Have Sex With Men and People Who Inject Drugs in India.</article-title>
            <source>Clin Infect Dis</source>
            <year>2020</year>
            <month>Jan</month>
            <day>02</day>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>304</fpage>
            <page-range>304-313</page-range>
            <pub-id pub-id-type="pmid">30840989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20713.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Geske</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bakalkin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Winham</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Karpyak</surname>
                <given-names>VM</given-names>
              </name>
            </person-group>
            <article-title>Correlations between sex-related hormones, alcohol dependence and alcohol craving.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>197</volume>
            <fpage>183</fpage>
            <page-range>183-190</page-range>
            <pub-id pub-id-type="pmid">30840924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20713.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eggink</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Waal</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Goudriaan</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Criminal offending and associated factors in dual diagnosis patients.</article-title>
            <source>Psychiatry Res</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>273</volume>
            <fpage>355</fpage>
            <page-range>355-362</page-range>
            <pub-id pub-id-type="pmid">30682557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20713.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham</surname>
                <given-names>TTL</given-names>
              </name>
              <name>
                <surname>Callinan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Livingston</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Patterns of alcohol consumption among people with major chronic diseases.</article-title>
            <source>Aust J Prim Health</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-167</page-range>
            <pub-id pub-id-type="pmid">30837058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20713.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <article-title>Drugs for chronic insomnia.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2018</year>
            <month>Dec</month>
            <day>17</day>
            <volume>60</volume>
            <issue>1562</issue>
            <fpage>201</fpage>
            <page-range>201-205</page-range>
            <pub-id pub-id-type="pmid">30625122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20713.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vorspan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barr&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pariente</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montastruc</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tournier</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Should the duration of treatment be limited using benzodiazepines?].</article-title>
            <source>Presse Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>10</issue>
            <fpage>892</fpage>
            <page-range>892-898</page-range>
            <pub-id pub-id-type="pmid">30454582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20713.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Philibert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Noel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krukow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Papworth</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cowley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beach</surname>
                <given-names>SRH</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide and digital polymerase chain reaction epigenetic assessments of alcohol consumption.</article-title>
            <source>Am J Med Genet B Neuropsychiatr Genet</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>177</volume>
            <issue>5</issue>
            <fpage>479</fpage>
            <page-range>479-488</page-range>
            <pub-id pub-id-type="pmid">29704316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20713.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alammehrjerdi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Briggs</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Biglarian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mokri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dolan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A Randomized Controlled Trial of Brief Cognitive Behavioral Therapy for Regular Methamphetamine Use in Methadone Treatment.</article-title>
            <source>J Psychoactive Drugs</source>
            <year>2019</year>
            <season>Jul-Aug</season>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>280</fpage>
            <page-range>280-289</page-range>
            <pub-id pub-id-type="pmid">30835643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20713.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Canan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Murimi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chander</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Medicaid trends in prescription opioid and non-opioid use by HIV status.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>197</volume>
            <fpage>141</fpage>
            <page-range>141-148</page-range>
            <pub-id pub-id-type="pmid">30825794</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
